<DOC>
	<DOCNO>NCT01838083</DOCNO>
	<brief_summary>Primary Objective : To demonstrate equivalence exposure insulin glargine give test formulation T reference formulation R steady state condition 6 once-daily subcutaneous ( SC ) dose Secondary Objective : - To assess relative Pharmacodynamic activity insulin glargine test formulation T insulin glargine reference formulation R steady state condition 6 once-daily SC dose - To assess safety tolerability test reference formulation two new insulin glargine formulation</brief_summary>
	<brief_title>Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Total study duration per subject : 29 64 day include screen visit Duration part study one subject : - Screening : 3 21 day 1st dosing ( Day -21 Day -3 ) - Treatment Period 1 2 : 8 day ( dose 6 day ) - Washout last/1st dose day treatment period : 7-21 day ( preferentially 7 day ) End-of-Study Visit : 7-10 day last dosing</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Male female subject , 18 64 year age , inclusive , diabetes mellitus type 1 one year Total insulin dose &lt; 1.2 U/kg/day Minimum usual basal insulin dose ≥ 0.2 U/kg/day Body weight 50.0 kg 110.0 kg , Body Mass Index 18.5 30.0 kg/m2 inclusive Fasting negative serum Cpeptide ( &lt; 0.3 nmol/L ) Glycohemoglobin ( HbA1c ) ≤ 75 mmol/mol [ ≤ 9.0 % ] Stable insulin regimen least 2 month prior inclusion study Certified otherwise healthy Type1 Diabetes mellitus patient Laboratory parameter within normal range Women childbearing potential negative pregnancy test use highly effective contraceptive method woman confirm postmenopausal status Exclusion criterion : Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic ( apart diabetes mellitus type 1 ) , hematological , neurological , psychiatric , systemic ( affect body whole ) , ocular , gynecologic ( female ) , infectious disease ; acute infectious disease sign acute illness . More one episode severe hypoglycemia seizure , coma require assistance another person past 6 month Frequent severe headache / migraine , recurrent nausea / vomiting ( twice month ) Symptomatic hypotension ( whatever decrease blood pressure ) , asymptomatic postural hypotension define decrease systolic blood pressure equal great 20 mmHg within three minute change supine stand position Presence history drug allergy clinically significant allergic disease accord Investigator 's judgment Likelihood require treatment study period drug permit clinical study protocol Presence history drug alcohol abuse ( alcohol consumption &gt; 40 gram / day ) If female , pregnancy ( define positive Beta Human Chorionic Gonadotropin test ) , breastfeed Known hypersensitivity insulin glargine excipients study drug Any history presence deep leg vein thrombosis frequent appearance deep leg vein thrombosis first degree relative ( parent , sibling child ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>